NeurogesX, which is developing pain management therapies based on known chemical entities, priced its 4 million shares at $11, 21% below the midpoint of the anticipated $13-$15 range, on Tuesday evening. Morgan Stanley was the lead manager on the deal. The stock...read more
NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the terms of its IPO Tuesday. The company plans to offer 4 million shares at $13.00 to $15.00 per share. Morgan Stanley is the lead...read more
NeurogesX, a biopharmaceutical company focused on developing on commercializing novel pain management therapies, filed for an IPO on Wednesday. Morgan Stanley is the lead manager on the deal. Terms and timing are yet to be announced....read more
ALERT: Top weekly perfomers: Rex Energy, NeurogesX, Babcock & Brown
The following companies were the top performing IPOs over the last five trading sessions:
...read more
Biotech NeurogesX prices below range
NeurogesX, which is developing pain management therapies based on known chemical entities, priced its 4 million shares at $11, 21% below the midpoint of the anticipated $13-$15 range, on Tuesday evening. Morgan Stanley was the lead manager on the deal. The stock...read more
Biopharmaceutical company NeurogesX announces terms
NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the terms of its IPO Tuesday. The company plans to offer 4 million shares at $13.00 to $15.00 per share. Morgan Stanley is the lead...read more
Biopharmaceutical company NeurogesX files for IPO
NeurogesX, a biopharmaceutical company focused on developing on commercializing novel pain management therapies, filed for an IPO on Wednesday. Morgan Stanley is the lead manager on the deal. Terms and timing are yet to be announced....read more